首页/数据集/Comprehensive target engagement by EZH2 inhibitor CPI-0209 allows for preferential targeting of ARID1A mutant urothelial carcinoma

Comprehensive target engagement by EZH2 inhibitor CPI-0209 allows for preferential targeting of ARID1A mutant urothelial carcinoma

NIAID Data Ecosystem2026-05-02 收录

尿路上皮癌

ARID1A突变药物响应

数据链接：

https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE176493 数据链接链接失效反馈

官方服务：

资源简介：

This SuperSeries is composed of the SubSeries listed below. Refer to individual Series

应用场景：

创建时间：

2024-06-29

尿路上皮癌

靶向测序

We analyzed data from over 600 patients and demonstrated that the combination of ARID1A loss and high CD8 + T cell infiltration defines a distinct subgroup of urothelial carcinoma (UC) with

Figshare2025-07-11 更新100

放射治疗

尿路上皮癌

This record contains raw data related to article "Stereotactic Body Radiation Therapy in the Management of Oligometastatic and Oligoprogressive Bladder Cancer and Other Urothelial Malignancies" Aims

NIAID Data Ecosystem70

Cutoff values for each of the studied genes.

尿路上皮癌

β2-整合素生物标志物

β2-integrins are a family of adhesion proteins expressed in immune cells that play multiple roles in anti-tumor immunity. β2-integrins regulate tumor infiltration of anti-tumorigenic immune cells such

Figshare2025-10-24 更新30

Supplementary Material for: Complete Response of Rare Sarcomatoid Upper Tract Urothelial Carcinoma Variant : Case Report and Literature Review

尿路上皮癌

肉瘤样变异体

Infiltrating urothelial carcinoma sarcomatoid variant is a rare variant of urothelial carcinoma. We report a case of a 68-year-old female with a history of hematuria. CT Scan with contrast showed a ma

DataCite Commons2025-06-01 更新80

Non-invasive diagnosis of urothelial cancer in urine using DNA hypermethylation signatures

尿路上皮癌

甲基化DNA生物标志物

Methylation status of free DNA from urine from patients with urothelial tumor and healthy control patients were analysed Patients with histologically confirmed urothelial cancer vs healthy control don

NIAID Data Ecosystem50

Comprehensive target engagement by EZH2 inhibitor CPI-0209 allows for preferential targeting of ARID1A mutant urothelial carcinoma

资源简介：

相关数据集